Several studies have indicated that patients with bipolar disorder (BD) who respond well to lithium prophylaxis constitute a biologically distinct subgroup. Lithium is thought to stablize mood by acting at the phosphoinositide cycle. We have investigated a polymorphism located in the gene (PLCG1) that codes for a ␥-1 isozyme of phospholipase (PLC), an enzyme that plays an important role in the phosphoinositide second messenger system. A population-based association study and a family-based linkage study were carried out on patients who were considered excellent responders to lithium prophylaxis. Response to lithium was evaluated prospectively with an average follow-up of 14.4 ± 6.8 years. The PLCG1 polymorphism was investigated in 136 excellent lithium responders and 163 controls. In addition, the segregation of this marker was studied in 32 families ascertained through lithium-responsive bipolar probands. The allele distributions between lithium-responsive bipolar patients and controls were different, with a higher frequency of one of the PLCG1 polymorphisms in patients ( 2 = 8.09; empirical P = 0.033). This polymorphism, however, confers only a small risk (OR = 1.88, CI 1.19-3.00). Linkage studies with the same marker yielded modest support for the involvement of this gene in the pathogenesis of BD when unilineal families were considered (Max LOD = 1.45; empirical P = 0.004), but not in the whole sample. Our results provide preliminary evidence that a PLC isozyme may confer susceptibility to bipolar disorder, probably accounting for a fraction of the total genetic variance. Whether this polymorphism is implicated in the pathogenesis of BD or in the mechanism of lithium response remains to be determined.
Several studies have indicated that patients with bipolar disorder (BD) who respond well to lithium prophylaxis constitute a biologically distinct subgroup. Lithium is thought to stablize mood by acting at the phosphoinositide cycle. We have investigated a polymorphism located in the gene (PLCG1) that codes for a ␥-1 isozyme of phospholipase (PLC), an enzyme that plays an important role in the phosphoinositide second messenger system. A population-based association study and a family-based linkage study were carried out on patients who were considered excellent responders to lithium prophylaxis. Response to lithium was evaluated prospectively with an average follow-up of 14.4 ± 6.8 years. The PLCG1 polymorphism was investigated in 136 excellent lithium responders and 163 controls. In addition, the segregation of this marker was studied in 32 families ascertained through lithium-responsive bipolar probands. The allele distributions between lithium-responsive bipolar patients and controls were different, with a higher frequency of one of the PLCG1 polymorphisms in patients ( 2 = 8.09; empirical P = 0.033). This polymorphism, however, confers only a small risk (OR = 1.88, CI 1.19-3.00). Linkage studies with the same marker yielded modest support for the involvement of this gene in the pathogenesis of BD when unilineal families were considered (Max LOD = 1.45; empirical P = 0.004), but not in the whole sample. Our results provide preliminary evidence that a PLC isozyme may confer susceptibility to bipolar disorder, probably accounting for a fraction of the total genetic variance. Whether this polymorphism is implicated in the pathogenesis of BD or in the mechanism of lithium response remains to be determined.
Bipolar disorder (BD) is a major psychiatric condition characterized by episodes of mania and depression, affecting up to 1% of the general population. 1 Lithium has been used in the prophylaxis and treatment of BD for almost half a century, and remains the first-choice therapy for preventing recurrences. 2 Although lithium is considered specific for the treatment of BD, with no comparable effect in other psychiatric disorders, its effectiveness varies widely. There is compelling evidence that lithium is more effective in forms of BD characterized by typical symptomatology and the absence of comorbidity. [3] [4] [5] There is also evidence that responders and nonresponders to lithium treatment differ in certain neuroendocrine responses involving the serotonergic and endorphin systems. 6 In addition, family studies indicate a higher recurrence risk for bipolar disorder among relatives of patients who respond well to lithium treatment. 5, 7, 8 Taken together, these findings suggest that response to lithium prophylaxis may help define a distinct bipolar phenotype with less genetic heterogeneity.
The mechanism by which lithium acts is not exactly known. Recent findings indicate that lithium may stabilize mood by acting at the phosphoinositide second messenger system. 9 Cellular responses mediated by inositol phospholipids are involved in many brain processes. 10, 11 They are initiated by a phospholipase C (PLC) isozyme after activation by a membrane receptor that can be coupled to a G protein, protein tyrosine kinase or several lipid-derived second messengers such as arachidonic acid. 12 Lithium is thought to inhibit the enzyme inositol monophosphatase, leading to a reduction in the availability of inositol. 9 In this study we present preliminary evidence suggesting that patients who have an excellent response to lithium prophylaxis have a higher frequency of a polymorphism located in the gene coding for the ␥-1 isozyme of phospholipase C (PLCG1) on chromosome 20. This result was further explored in a family linkage study.
Patients with bipolar disorder were recruited from six centers that collaborate in the International Group for the Study of Lithium (IGSLI) (see methods). These patients have been followed in specialized lithium clinics and their response to lithium prophylaxis has been assessed systematically and prospectively. In order to be included in the study, all patients had to meet stringent criteria of excellent lithium response, described previously 5 and summarized in Table 1 . A total of 136 patients were included in the association study. The mean (± standard deviation) age of onset was 27.6 (± 9.9) years. The number of the illness episodes prior to lithium treatment was 8.2 (± 10.1). Patients have been stabilized on lithium monotherapy for 14.4 (± 6.8) years. Control subjects for this study were 128 psychiatrically unaffected individuals who were collected in similar fashion by participating centres, and consisted of healthy married-in individuals from the linkage study, hospital staff and normal volunteers. Thirty-five more control subjects were included without assessment of psychiatric status. All cases and controls were of similar ethnic background and were, whenever possible, matched for geographical origin. The mean age (± standard deviation) and sex ratio (M : F) were 50.0 (± 14.4) years, 0.87 for patients and 51.45 (± 14.8), 0.86 for controls. Thirty-two of the Canadian probands had families available for linkage analysis. The family sample consisted of 224 interviewed and genotyped individuals, of whom 95 were affected.
Allele distributions in individuals from different centers were similar, both for cases ( The distributions of alleles in patients and controls are shown in Table 2 . A significant difference was observed in the overall allele frequency distribution between patients and controls ( 2 = 23.22: d.f. = 13, P = 0.029 * ) with allele PLCG1/5 being considerably more frequent among patients than controls ( 2 = 8.09; d.f. = 1, P = 0.033* and OR = 1.88, CI 1.19-3.00). In order to take into account possible instability of the dinucleotide repeat, we examined whether the difference between groups remained within the bounds of alleles with ± 1 and ± 2 repeats. Indeed, patients differed from controls when these alleles were pooled *Indicates empirical P values observed using Monte Carlo simulations (see methods).
together (PLCG1/5 ± 1: 2 = 10.35; d.f. = 1, P = 0.007* and PLCG1/5 ± 2: 2 = 7.59; d.f. = 1, P = 0.019*). Furthermore, patients and controls also differed when alleles were grouped according to size, with patients presenting an excess of long (CA) n repeats (PLCG/1-PLCG/7), whereas controls have predominantly short (PLCG1/8-PLCG1/18) variants ( 2 = 8.30; d.f. = 1, P = 0.007*) (see Figure 1) .
Parametric linkage results using the PLCG1 marker gave non significant maximum lod scores when results from all families were considered (see Table 3 ). Individuals were considered affected when they met RDC criteria for bipolar disorder, schizoaffective disorder or recurrent major disorder. Three major genetic models were explored in order to maximize the evidence for linkage. These models were: (a) dominant (allele frequency (q) 0.012, male penetrance (fM) 0.4, female penetrance (fF) 0.7, and normal penetrance 0.005 for males (fM0) and 0.009 for females (fF0)); (b) intermediate
As previous findings suggested that the study of unilineal pedigrees may provide an advantage to overcome part of the complexity of BD, [13] [14] we further analyzed the data according to lineality. Among all pedigrees, 13 were clearly unilineal (six of paternal and seven of maternal origin). The largest lod score observed among unilineal families was 1.45 (P = 0.004) under the dominant model. Similar results in these families were found using a narrower diagnostic definition, which excluded recurrent major depression (Z max = 1.02, P = 0.006). There was no difference between maternal and paternal pedigrees. Nonparametric linkage analysis provided similar results (see Table 3 ).
An increasing body of evidence supports the hypothesis that alterations in the phosphoinositide signal transduction system may be implicated in the pathophysiology of bipolar disorder. 9, 15 Studies of postmortem brains from patients with BD and suicide victims with major depression have shown a marked reduction in phosphatidylinositol hydrolysis by G protein coupled to phospholipase C stimulation, when compared to normal controls. 15, 16 Furthermore, recent magnetic resonance spectroscopy studies have indicated that lithium reduces myoinositol levels in critical brain regions in bipolar patients. 17 The phosphoinositidespecific PLC ␥-1 isozyme is present in neurons; studies in rats have found it highly localized in the hippocampus and basal ganglia.
11 PLC ␥-1 is activated by a number of receptors that promote phosphorylation of the enzyme, usually via protein tyrosine kinase, resulting in the hydrolysis of phosphatidylinositol 4,5-biphosphate. This produces two intracellular messengers: diacylglycerol and inositol 1,4,5-triphosphate. 12 It is therefore possible that PLCG1 variants account for a proportion of the total genetic variability predisposing to BD.
The finding of an association between PLCG1 and BD in our study suggests that this polymorphism is in linkage disequilibrium with the sequence/gene that confers susceptibility to BD. This interpretation is supported by the observation that, compared to controls, patients have a higher frequency of alleles within the bounds of ± 2 repeats from the associated allele. Furthermore, microsatellite repeats are usually not transcribed, and are therefore commonly regarded as non-functional, unlikely to confer susceptibility to BD.
However, there is increasing evidence that certain tandem repeat sequences, such as VNTRs do influence gene transcription, thereby influencing phenotype expression. 18, 19 In addition, comparative genomic studies have indicated that repeat arrays and genomic locations of dinucleotide repeats are highly conserved, suggesting that (CA) n repeats may have a functional significance. 20 Their role has been hypothesized to be, among others, related to the regulation of gene transcription. Therefore, it is possible that the microsatellite marker tested in this study by itself confers certain susceptibility to BD. Based on the observation that patients present longer (CA) n repeats than controls, one possible hypothesis would be that long alleles determine different gene transcription rates, predisposing individuals to BD.
Finally, we cannot exclude the possibility that our finding is spurious. It is conceivable that our results reflect problems such as admixture or population stratification effects, rather than a functional genetic association. 21 Although possible, it is unlikely that our findings result from admixture effect because samples were drawn from panmictic, non-isolated populations of similar ethnic origin. Moreover, when data from different centers were compared, both stratified and not stratified for clinical status, no differences in allele frequency distributions were observed.
The linkage results obtained for unilineal families in the parametric analysis, as well as those observed for the nonparametric linkage analysis were not significant given the standard criteria suggested for linkage studies. 22 However, these results are congruent with those obtained in the association study and warrant further consideration. Defining thresholds of significance in linkage studies of complex traits has been rather difficult. [22] [23] [24] [25] It is clear that in order to avoid false positive results, stringent criteria should be used. 22 This may lead, however, to situations in which samples of 'realistic' size will not have sufficient power to detect loci that account for a small proportion of the total genetic variability. 23 Considering the genetic and phenotypic complexity of BD, as well as the modest risk attributed to the PLCG1 locus, it is likely that our family sample was not large enough to achieve conventional significance levels. Hence, the results of the linkage study observed in unilineal families should be further explored as they may also be indicating that variation of PLCG1 may play a role in the pathogenesis of lithium-responsive BD.
Further evidence supporting the involvement of this locus in the etiology of BD will have to come through independent replication. Consistency between studies is an important way to validate findings. In this context, it is important to note that the patient cohort used in our study was carefully selected according to a systematic and prospective evaluation of lithium response. This locus could therefore be related to the responsiveness to lithium treatment rather than to bipolar disorder itself. However, the design of the present study does not allow us to further explore this issue. Thus, the validity of future attempts at independent replication of these findings will accordingly be contingent on lithium response being evaluated using similar methodology and criteria.
In conclusion, we have obtained preliminary evidence that a polymorphism at the locus that codes for a PLC isozyme is associated with BD in patients with an excellent response to lithium. Whether the locus that confers susceptibility to BD is the (CA) n , another polymorphism/mutation in the PLCG1 gene or another neighbouring gene remains to be clarified. We are currently conducting studies investigating this gene for additional polymorphisms which may be similarly associated with this disorder. In addition, we are in the process of collecting a group of lithium non-responders which may help to address important points related to the specificity of this finding.
Methods

Patient ascertainment and diagnostic assessment
Patients for the association study were recruited as follows: 68 from Canada, 21 from Germany, 20 from the Czech Republic, 17 from Sweden, seven from Denmark, and three from Austria. Families for the linkage study were collected only among Canadian probands. Thirty-two had positive family history and were cooperative. Families were considered when they met the following criteria: first, at least four family members (including the proband) must have been available for interview and blood sample. Of these, at least two subjects must have been affected. Second, at least one of the proband's parents must have been unaffected. Finally, only subjects older than 15 years were asked to participate. The pedigrees were extended in such a way as to include all first-degree relatives of all affected subjects. As the penetrance is presumably low, all firstdegree relatives of all subjects whose first-degree relatives were affected were included. The procedure for an extended sampling of families for linkage analysis was based on the rule proposed by Cannings and Thompson. 26 All diagnoses were based on the Schedule for Affective Disorders and Schizophrenia 27 (SADS-L) interview and Research Diagnostic Criteria 28 (RDC). All diagnostic and treatment information was reviewed by a panel of experienced psychiatrists in a blind fashion. To further ensure uniformity of diagnoses in six different countries, all subjects were subsequently assessed by the same senior clinician (PG). All patients were Caucasians of Western and Central European descent. All individuals included in the association and linkage studies provided written informed consent.
For linkage analyses, two phenotypic schedules were used. Under the first one, relatives were considered affected if they met RDC criteria for bipolar disorder, schizoaffective disorder or recurrent major depression with the additional criterion of functional impairment during depressive episodes. Under the second phenotypic schedule, only subjects with bipolar and schizoaffective disorders were considered affected while the phenotype of unipolar depression was treated as unknown. Pedigrees were considered unilineal if the trait segregated exclusively through one of the proband parent's family. More specifically, the parent, this parent's parents and siblings had to be unaffected. This is consistent with published criteria for lineality assessment.
PLCGI genotyping
Genomic DNA was extracted by a standard method 29 from venous blood samples. The PLCG1 polymorphism was originally identified by searching a cosmid isolated using a clone containing the PLCG1 cDNA. This is an untranslated (CA) n repeat with 14 observed alleles ranging in size from 150 to 184 bp. 30 PCR was carried out in a total volume of 12.5 l containing 40 ng genomic DNA; 125 ng of primers PLCpr1 (5′-AAC-CAGTCTGCTCTTCCGGTG-3′) and PLCpr2 (5′-CTGCCTTCAACTGATCTCAATGG-3′); 200 M each of dGTP, dCTP, and dTTP; 25 M dATP; 1.5 Ci[
35 S]DATP; 0.5 units of Taq DNA polymerase (Bio/Can Scientific, Toronto, Canada); and 2.0 l of 10× buffer (Bio/Can Scientific) with MgCl 2 included in the final concentration of 1.5 mM. Samples were over-laid with mineral oil and processed throughout 35 cycles of denaturation at 94°C, annealing at 56°C, and elongation at 72°C, followed by a final elongation period of 72°C. PCR products were analyzed on a 6% denaturating polyacrylamide gel (38 : 2 acrylamide : bisacrylamide): Samples were run for a period of 2 h in a vertical electrophoresis gel apparatus (Life Technologies, Gaithersburg, USA). Gels were dried and exposed to X-ray films for 48-72 h at room temperature. All marker determinations were made blind to the clinical diagnoses. Autoradiographs were read and interpreted independently by two different readers, and both readings yielded identical results.
Statistical analysis
The presence of an association was investigated using 2 and odds ratio tests by standard methods using the BMDP statistical package. 31 In addition, we analyzed the data using the method proposed by Curtis and Sham that estimates empirical P values using a Monte Carlo approach 32 (implemented in the computer program CLUMP). This method is particularly suitable for the analysis of tables with a large number of columns and sparse cells, and therefore has large application in association studies using highly polymorphic markers, such as this one. The advantage of this method is that it provides a robust and useful alternative to the excessively conservative Bonferroni correction in cases where the observed contingency tables have a large number of columns. 32 Parametric linkage analysis was carried out using the MLINK 33 program of the FASTLINK 34 package. To determine the empirical level of significance of the observed linkage results, simulations were carried out using the SIMULATE 35 and SLINK 36, 37 programs. Nonparametric linkage analysis was conducted using the SimIBD program which calculates a simulation-based nonparametric statistic that provides a powerful test for linkage. 38 Empirical P values both for parametric and nonparametric linkage analysis were estimated by running 1000 simulations. For the contingency tables, 10 000 simulations were used.
